Smooth Drug Development starts a new bioequivalence trial

Smooth Drug Development starts a new bioequivalence trial of a non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties.

The client is a global pharmaceutical and biotechnology organisation, providing affordable, high-quality medicines for a healthier world.

Our clients are leading pharmaceutical, biotech and R&D companies. Our customers are located in Russia, Europe, US and Asia-Pacific region.

Smooth Drug Development, a leading CRO in Russia, CIS and Baltic countries, provides a full range of services for clinical research since 2011.